Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brivaracetam - UCB Pharma

Drug Profile

Brivaracetam - UCB Pharma

Alternative Names: BRIVIACT; BRIVLERA; RIKELTA; UCB-34714

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB
  • Class Antiepileptic drugs; Neuroprotectants; Non-opioid analgesics; Nootropics; Pyrrolidinones; Small molecules
  • Mechanism of Action Sodium channel antagonists; SV2A protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myoclonic epilepsies
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Discontinued Myoclonic epilepsies; Postherpetic neuralgia

Most Recent Events

  • 26 Sep 2018 UCB Biopharma plans a phase III trial for Epilepsy in October 2018 (NCT03685630)
  • 09 Jul 2018 Brivaracetam licensed to for distribution and marketing to Dr. Reddy's Laboratories in India
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top